Revolution Medicines jobs

Associate Director, Accounting - Japan Remote (Japan) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking an experienced, strategic, and hands-on accounting leader to build and scale the accounting and finance operations infrastructure in Japan. Reporting directly to the Head of Finance & Operations, Japan, this newly created role will play a critical role in supporting the company's transition toward future commercial readiness and long-term growth in Japan. This position will lead core accounting operations, financial systems implementation, process design, internal controls, and statutory compliance, while partnering cross-functionally to establish a scalable and compliant finance environment capable of supporting a commercial-stage organization. The role will also serve as a key business partner across Finance, Commercial, Legal, Supply Chain, HR, and global teams to help prepare the organization for future product launches and increasing operational complexity. The ideal candidate combines strong technical accounting expertise with operational leadership, systems implementation experience, and the ability to build processes and infrastructure

Principal Product Manager, Clinical Trials Intelligence Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a Principal Product Manager, Clinical Trials Intelligence to build products that help teams plan, run, monitor, analyze, submit, and follow clinical trials with greater speed, quality, and confidence.This role will define and deliver product strategy across the clinical trial continuum, from study design and startup through trial conduct, submission readiness, and post-approval safety monitoring. You will shape Clinical Trials Intelligence capabilities on RevCore, our enterprise data and AI platform, with a clear mandate to improve trial execution, enrollment predictability, data readiness, submission readiness, inspection readiness, and safety monitoring. You will work on high-stakes products where trust, usability, traceability, and speed directly affect trial execution, regulatory readiness, and patient impact. This role focuses on product strategy, user outcomes, workflow design, adoption, and measurable impact, in partnership with clinical, regulatory, safety, medical, data, technology, quality, vendor, and system owner teams.

Executive Director, Global Scientific Communications Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: As a new member of the Revolution Medicines team, the Executive Director, Global Scientific Communications will lead the development and execution of a comprehensive scientific communications strategy and team, ensuring alignment across internal and external stakeholders in preparation for the company's first commercial launch in pancreatic cancer and the progression of additional pipeline assets in NSCLC, colorectal cancer, and other solid tumors. Reporting into the SVP, Global Medical Affairs, this role will will be responsible for leading our scientific communications platforms and publication strategies and contribute to medical content supporting the organization's medical and scientific engagement efforts. Key responsibilities include: Publications Strategy & Execution - Lead the development and execution of the global publication plans, ensuring alignment with clinical and scientific objectives. - Oversee and provide strategic direction for medical writing, publication planning meetings, the submission process, and timely/high-quality scientific communications and

Associate Director, Regulatory Systems Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Regulatory Business Systems will lead the strategy, governance, implementation, and optimization of Regulatory Affairs technology platforms that support global regulatory operations and submission activities. This individual will serve as the business owner for key regulatory systems and partner closely with Regulatory Affairs, Regulatory Operations, IT, Quality, Clinical, and external vendors to deliver scalable, compliant, and efficient business solutions. The ideal candidate brings deep expertise in regulatory processes, business systems management, and cross-functional collaboration within a biotechnology or pharmaceutical environment. This role will play a critical part in advancing RevMed's regulatory systems roadmap and enabling operational excellence across the regulatory organization. Key Responsibilities: - Serve as the business owner and strategic lead for Regulatory Affairs systems, including Veeva RIM, Veeva Registrations, DocuBridge, and related regulatory platforms. - Drive the long-term strategy, roadmap, and governance model for regulatory business systems aligned with

Senior Director, Commercial, France Paris, France Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, Commercial, France is responsible for defining and executing the local commercial strategy for oncology products. This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions. The incumbent needs to proactively recognize and address relevant systemic (e.g. health care structures, competitors, data gaps, diagnostic challenges, missing advocacy) and HCP related opportunities (e.g. therapeutic gaps, differentiation, economical attributes, clear messaging of patient- and physician relevant benefits). The Senior Director Commercial will further oversee the generation of insights from the therapeutic field, and translate these insights into a comprehensive, cross-functional strategy. Supporting a clear positioning and aligned communication approach, the incumbent will in addition secure the development and implementation of tactics and tools for the field force to effectively address customer needs. Responsibilities: - Act as the Commercial Lead

Senior Financial Analyst/Finance Manager Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Revolution Medicines is seeking a Sr. Financial Analyst/Finance Manager to support our growing needs in Development and R&D Finance. The successful candidate will have experience with clinical trials, R&D accruals process, month-end close, financial reporting, SOX, and audit support. This position is based out of our headquarters in Redwood City, CA. - Reporting to the Associate Director, FP&A and will serve as a business partner to Clinical Operations and cross-functional partner to Accounting, Finance, and Procurement. - Prepare month-end clinical trial accruals, including review of CRO reports, patient costs, and site payments. - Prepare monthly and quarterly reconciliations for accrued clinical and related prepaid accounts. - Contribute to Identify, design, and implement process improvements to streamline clinical trial accruals, reducing manual effort and improving accuracy and timeliness. - Review contracts and amendments to analyze and determine impact on clinical accruals. - Prepare contract

Director, Medical Analytics and Exploratory Data Science Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly motivated and scientifically rigorous Director of Biostatistics to our Medical Analytics and Exploratory Data Science Biostatistics group. This role will provide strategic and hands-on statistical leadership for exploratory data analyses, scientific publications, real-world evidence (RWE), post-marketing research, and health economics and outcomes research (HEOR) initiatives. The successful candidate will serve as a key statistical leader and individual contributor, partnering closely with cross-functional teams to generate high-quality evidence that advances our oncology pipeline and supports medical and scientific strategy. - Provide statistical leadership for exploratory data analyses using existing clinical trial data, real world data studies, post-marketing research, and HEOR projects. - Serve as a primary statistical contact for assigned projects, working collaboratively with clinical development, medical affairs, safety, statistical programming, regulatory affairs and commercial. - Lead the design, analysis, and interpretation of complex statistical models,

Senior Director, Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced clinical science drug developer to serve as Senior Director of Clinical Development in support of Revolution Medicines' clinical-stage molecule(s). In this critical role, you will support various clinical science deliverables and enable effective and efficient execution of the clinical development plan for a molecule(s) within its particular indication(s). The scope of activities spans early-stage clinical research to pivotal studies including regulatory submissions. You will play a vital role in leading the clinical science aspects of the Clinical Development Plan (CDP) strategy, driving the development of transformative therapies for patients. - Lead clinical science aspects of the clinical development strategy and clinical documentation. Represent the clinical development plan on appropriate teams, sub-teams and forums; oversee training of study site personnel, act as primary point-of-contact for questions/enquires regarding the CDP at a program level, oversee the conduct of medical/safety data

Vice President, Regulatory Affairs Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Vice President, Regulatory Affairs will manage several key U.S. based regulatory functions and report to the SVP of Regulatory and Quality. The position is responsible for expanding and leading a large, high functioning regulatory group and ensuring global alignment. - Provide ethical and mission-driven leadership of the Regulatory Affairs functions. Embody and practice the company's mission-driven culture. Ensure that our core values guide our strategic vision and our day-to-day decision making. - Provide a vision for the Regulatory Affairs organization and develop a plan to achieve it. Design and rapidly scale a group to meets the needs of an explosive pipeline in areas of high unmet medical need and intense industry competition. - Influence decision-making of senior leadership and ensure globally aligned regulatory decision-making. - Collaborate closely and form effective relationships with other functional heads and regional counterparts to ensure high quality,

Vice President, Global CMC Regulatory Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an accomplished, strategic and execution-oriented leaders, Vice President, Global CMC Regulatory, reporting to SVP of Pharmaceutical Development and Manufacturing (PDM) Regulatory, to lead our global chemistry, manufacturing, and controls (CMC) regulatory strategy and execution across all development programs and commercial assets. This leader will drive regulatory strategy development, lead regulatory interactions, and provide expertise throughout the product lifecycle, from early development to post-approval variations ensuring the timely submission and approval of high-quality CMC regulatory filings to support our company's pipeline and global growth. The successful candidate will serve as a senior leadership role within Pharmaceutical Development and Manufacturing (PDM) organization, overseeing CMC regulatory activities and ensuring alignment with health authority expectations globally (FDA, EMA, PMDA, NMPA, etc.). The role requires expertise in small molecule pharmaceutical development and manufacturing, an understanding of the oncology development lifecycle, and the ability to

Vice President, Analytical Development & Quality Control Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a strategic and execution-driven Vice President, Analytical Development & Quality Control (ADQC) to lead the vision, strategy, and execution of analytical development and QC across our growing portfolio. Reporting to the Senior Vice President, Pharmaceutical Development & Manufacturing, this executive will build and scale a phase-appropriate, forward-looking analytical organization that enables rapid development of small molecule programs while positioning the company for late-stage development and global commercialization. As a key member of the PDM leadership team, this role will shape analytical strategy at the enterprise level, ensuring robust control strategies, regulatory readiness, and operational excellence across internal and external networks. Responsibilities: Strategic & Organizational Leadership - Define and drive the enterprise-wide analytical development and QC strategy aligned with portfolio and corporate objectives. - Build, lead, and scale a high-performing ADQC organization to support a multi-asset oncology pipeline.

Associate Director, Clinical Operations Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: This is a unique opportunity for a Clinical Operations Professional who has innate leadership and organizational skills, technical expertise in clinical oncology drug development in an industry setting, and experience in overseeing clinical trials. As an Associate Director, you will be responsible for the Contract Research Organization (CRO) oversight, execution, and management of Revolution Medicines (RevMed) clinical trials. Responsibilities: - Adhere to Clinical Standard Operating Procedures (SOP) and Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines. - Global experience in end-to-end execution of different phases of clinical trials. - Accountable for study delivery goals. Oversee the successful management of all aspects of clinical trials within timelines and designated program budgets. - Guide assessment, selection, engagement, management, and oversight of appropriate vendors. - Responsible for making decisions that balance risk/benefit with clear understanding of impact on the study and project; takes

Executive Director, Quality, Europe Remote (Netherlands) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Executive Director, Head of Quality, Europe is responsible for leading and overseeing all Quality functions across the European region, ensuring compliance with European regulatory requirements. This role provides strategic and operational leadership across GxP Quality (GMP, GDP, GCP as applicable). In addition, this role serves as the key Quality representative for Europe, partnering closely with Regulatory Affairs, Manufacturing, Supply Chain, Clinical Operations, and external partners to ensure a robust and inspection-ready quality system. Key Responsibilities: - Lead and develop the European Quality organization, ensuring alignment with global quality strategy and supporting the transition from clinical to commercial operations. - Act as the primary Quality representative for Europe, providing leadership in regional and global governance forums and serving as the main interface with European regulatory authorities (e.g., EMA, national agencies). - Ensure Quality oversight of MAH responsibilities, including lifecycle management, product complaints, recalls, and fulfillment of

Associate Director, Global Quality System & Compliance Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: - Provide strategic and operational leadership to scale and globalize the Quality Management System (QMS), establishing a harmonized, flexible framework that supports international growth and regulatory compliance. - Lead oversight and expansion of core quality systems across global sites, including document control, GxP training, quality events, supplier management, audits, and batch release. - Partner with regional teams (including Japan, Europe & other global regions) to integrate local regulatory requirements into the global QMS while maintaining global consistency. - Establish and govern global quality procedures, including policies, SOPs, and standardized processes to ensure compliance and operational efficiency. - Ensure inspection readiness and lead support for global health authority inspections, regulatory submissions, and product launches. - Oversee global quality metrics, compliance monitoring, and management review processes; drive proactive identification, escalation, and mitigation of quality risks. - Provide governance for electronic quality and

Associate Director, Regulatory Operations, Europe Basel, Basel-Stadt, Switzerland Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Regulatory Operations, Europe will play a key role in supporting the growing European Regulatory Affairs organization by leading the operational planning and execution of regulatory submissions across the region. This role partners closely with the European Regulatory Affairs team to operationalize regional regulatory strategies and ensure successful execution of regulatory submissions to health authorities across the EU, EEA, UK and Switzerland. Working cross-functionally with regulatory strategy, clinical, CMC, nonclinical, and quality teams, the Associate Director will drive submission planning, manage regulatory documentation, and coordinate cross-functional teams to deliver high-quality submissions in accordance with global and regional regulatory operations processes and systems. While primarily focused on the European region, this role operates within Global Regulatory Operations and may support regulatory submissions in other regions as business needs evolve. Primary Responsibilities: - Serve as the primary Regulatory Operations partner supporting the European Regulatory

Senior Director, Clinical Data Management Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director of Clinical Data Management provides high-level leadership for data management functions within clinical research, focusing on strategic development, operational execution, and regulatory compliance to ensure data integrity for clinical trials. Key responsibilities include leading and managing data management teams, establishing and enforcing data management policies and procedures, overseeing departmental budgets, collaborating with cross-functional teams and vendors, and ensuring data management processes meet regulatory standards. This role requires extensive experience in clinical data management, strong leadership and communication skills, expertise in clinical trial methodologies, and a deep understanding of regulatory requirements including submissions and data management systems. Required Skills, Experience and Education: - Define and implement the overall vision, strategy, and goals for the clinical data management department, including developing and enforcing departmental SOPs. - Lead, manage, and develop data management teams, handling resource planning, staff training, and performance reviews.

Senior Manager, Compliance - Field Commercialization (West) Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Manager, Compliance - Field Commercialization is responsible for providing hands-on support to Commercial and Medical field teams during product commercialization and indication expansion. This role serves as a primary field-facing compliance partner, ensuring compliant execution of field activities while enabling business objectives. Reporting to the Senior Director, Compliance the Senior Manager will implement and continuously enhance a comprehensive field-facing compliance program, embedding compliance into daily field operations while supporting the company's growth as commercial stage oncology organization. Field Compliance Support - This role will support the Senior Director, Compliance in providing field-facing corporate compliance support for all Revolution Medicines (RevMed) field roles, including field Sales, field Marketing, Medical Science Liaisons, and field Reimbursement and Access teams. - This role will serve as primary compliance contact for questions related to field activities. - The Senior Manager will partner with

Director, Global Value, Access & Pricing – CRC Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Director, Global Value, Access & Pricing - CRC is responsible for developing and driving global access and pricing strategies for Revolution Medicines' CRC assets to enable timely, sustainable patient access across key markets. This role ensures payer and HTA requirements are embedded into clinical development, indication sequencing, and launch planning from early-stage development through commercialization. The Director serves as the global access lead on cross-functional asset teams and partners closely with HEOR, Clinical Development, Regulatory, Commercial, Finance, and Regional Market Access to align global strategy with regional execution. Key responsibilities: - Lead development of global pricing and market access strategies for CRC assets, including launch sequencing, reference pricing considerations, and price corridor management across priority markets. - Identify payer-relevant evidence requirements and partner with HEOR to align evidence generation plans with global reimbursement needs. - Assess CRC competitive dynamics, including

Associate Director, Medical Analytics and Exploratory Data Science Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a highly capable Associate Director of Biostatistics to join our Medical Analytics and Exploratory Data Science Biostatistics group within our Biostatistics organization. This role will play a critical part in the design, analysis, and interpretation of exploratory data analyses, scientific publications, real-world evidence (RWE), post-marketing research, and health economics and outcomes research (HEOR) studies. The successful candidate will serve as a key statistical contributor and emerging leader, partnering closely with cross-functional teams to deliver high-quality, data-driven insights that support scientific understanding and evidence generation. - Lead statistical design, analysis, and interpretation for exploratory data analyses using existing clinical trial data, real world data studies, post-marketing research, and HEOR projects. - Partner closely with other subfunctions within quantitative sciences and with cross-functional teams, including clinical development, medical affairs, safety, statistical programming, regulatory affairs and commercial, to execute

Global Development Lead (GDL), Clinical Development Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking an experienced oncology drug-development leader to serve as Global Development Lead (GDL) for one of Revolution Medicines' most advanced clinical programs. This is a senior, program-accountable leadership role with end-to-end ownership of clinical development strategy and execution for a late-stage asset, including pivotal studies, regulatory engagement, and long-range planning. The GDL functions as the single point of clinical accountability for the assigned program, setting direction, driving alignment across functions, and representing the program at internal governance bodies and externally with investigators, key opinion leaders, and global health authorities. This position sits at the Executive Director level within Clinical Development and carries program-level accountability and authority typically associated with the most senior clinical leaders in the organization. In addition to program ownership, the GDL serves as a senior clinical advisor to development leadership, contributing perspective to cross-program and enterprise-level

Senior Scientist I, Computational Chemistry Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: We are seeking a motivated Senior Scientist I to join our dynamic Computational Chemistry team.This position offers an exciting opportunity to drive drug discovery through cutting-edge computational methods, working at the intersection of structural biology, medicinal chemistry, biology, and data science to accelerate the development of transformative therapeutics for patients. As a key contributor in our Computational Chemistry team, you will: - Partner with multidisciplinary, collaborative teams in Discovery Sciences to design, optimize, and accelerate the discovery of novel drug candidates using structure-based computational methods. - Analyze structure-activity relationships (SAR) and make data-driven decisions by systematically following existing SAR trends to guide compound prioritization and design strategies for Ro5 and bRo5 molecules. - Partner closely with Medicinal Chemists to prioritize compound designs both independently and collaboratively, effectively communicating scientific rationale and recommendations to diverse interdisciplinary teams. - Design and implement virtual screening

Associate Principal Statistical Analyst Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Position requires 14+ years of Statistical Programming experience with exploratory-stage oncology clinical trials, providing programming support and oversight of one or more clinical programs (early or late phase) within Statistical Programming function. In addition to hands-on Programming, this position requires providing oversight and programming support and guidance for internal deliverables and regulatory submissions while ensuring conformance to CDISC standards and submission guidelines. Based on company needs, this position will be required to lead one or more early Phase or late phase studies/programs. Specific responsibilities include: - Effective collaborating with cross functional teams to provide programming timelines for various deliverables. - Provide SAS Programming technical support and guidance to programming team. - Oversight/participation in any internal/mock or regulatory authority audits. - Timeline and vendor management for deliverables, including submission-related activities, complying with regulatory standards (e.g., FDA 21 CFR Part 11, GxP). - Oversee the

Director, Target Biology Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Targets and Mechanisms group within Discovery Biology leverages expertise in cancer biology and deep mechanistic understanding of cancer-relevant pathways to identify and characterize high-priority oncology targets for our tri-complex inhibitor (TCI) platform. We are looking for an experienced drug hunter to lead the Target Biology team, provide hands-on scientific and people leadership, and work cross-functionally to identify and rapidly assess promising new targets, determine hit identification strategy, and advance screening hits through the early stages of hit-to-lead discovery. The ideal candidate will be a strategic thinker and an accomplished scientist with experience identifying and vetting targets for oncology programs, familiarity with different targeting modalities, including molecular glues, and hands-on hit to lead experience. In this role you will: - Lead a team of scientists focused on target identification, prioritization, and biological validation. - Work cross-functionally with partners in Medicinal Chemistry, Structural Biology, Discovery

Senior Specialist, Clinical Supply Chain Redwood City, California, United States Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Independently support global clinical supply chain operations across multiple studies. This role is ideal for a detail-oriented, proactive professional who thrives in a fast-paced environment and can manage study-level supply planning, execution, and vendor coordination with minimal oversight. - Independently manage clinical supply chain activities for assigned studies, including planning, execution, and reconciliation. - Support global depot and site distribution, including coordination of Qualified Person (QP) release, import/export logistics, and temperature-controlled shipments. - Lead clinical label design, packaging, and labeling activities in collaboration with internal teams and external vendors. - Serve as the primary point of contact for CMOs, depots, and IRT vendors for assigned studies. - Develop and maintain study-level supply plans and forecasts, adjusting for protocol amendments, enrollment trends, and country/site activation. - Manage IRT system setup and maintenance, including drug assignment logic, inventory thresholds, and expiry management. - Monitor